💊Public Meeting on Financial Transparency for Prescription Drug Fees
The Food and Drug Administration (FDA or the Agency) is announcing the following public meeting entitled "Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments." The topic to be discussed is the financial transparency and efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments.
Learn More📈OMB Review and Comment Request on Regulation ATS, Rule 304
The Securities and Exchange Commission has announced a request for OMB review regarding Rule 304 of Regulation ATS, which establishes compliance requirements for alternative trading systems. This rule, including Form ATS-N, aims to enhance operational transparency, promote competition, and ensure market participants are informed about ATS operations and potential conflicts of interest.
Learn More